Kailera Therapeutics serves as a clinical-stage biopharmaceutical company focused on developing a portfolio of therapies for obesity and related conditions. The company offers a range of clinical and preclinical programs including injectable and oral peptides, as well as an oral small molecule, all designed to manage chronic weight conditions such as obesity and type 2 diabetes.